ASH 2017 Conference Review

In this review:

Younger age is the only donor characteristic associated with survival
Edoxaban vs dalteparin for VTE disease associated with cancer
Caplacizumab in acquired thrombotic thrombocytopenic purpura
IW-1701 attenuates inflammation in TNF-α-treated mice
Effects of eculizumab on fibrinogen and clot structure in PNH
Second allogeneic SCT for acute leukemia in children
Brentuximab vedotin in previously untreated advanced Hodgkin lymphoma
Venetoclax in treatment-naïve, elderly patients with AML
CAR-T cell therapy in refractory DLBCL

Please login below to download this issue (PDF)

Subscribe